Advanced Biomed Inc.
Company Information
Industry
Services-Medical Laboratories
SIC Code
8071
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
NV
Business Address
401 RYLAND ST, RENO, NV, 89502
Mailing Address
401 RYLAND ST, RENO, NV, 89502
Phone
86-21-20510823
Fiscal Year End
0630
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 13, 2026 | View on SEC |
| 8-K/A Current report amendment | February 10, 2026 | View on SEC |
| 8-K Current report of material events | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 27, 2026 | View on SEC |
| 8-K Current report of material events | January 21, 2026 | View on SEC |
| 8-K Current report of material events | December 30, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 19, 2025 | View on SEC |
Annual Reports
10-K
October 8, 2025
- Launched 2 new products and won FDA approval for breakthrough blood-test device
- Revenue grew 15% year-over-year to $520 million
Material Events
8-K
Financial Distress
March 16, 2026
High Impact
- Advanced Biomed Inc. successfully regained Nasdaq compliance, avoiding delisting.
- The company can now maintain its access to crucial capital markets, essential for funding its research and development.
8-K
Strategy Change
February 26, 2026
High Impact
- Helps meet Nasdaq listing requirements, preventing delisting.
- Maintains market access and visibility, crucial for attracting institutional investors and capital.
8-K
Strategy Change
January 27, 2026
High Impact
- Potential for a nearly $7 million cash infusion, significantly boosting liquidity and overall financial health.
- Strengthens the balance sheet, improves current assets, and streamlines financial reporting by divesting a subsidiary.
8-K
Financial Distress
January 21, 2026
High Impact
- Advanced Biomed is actively appealing Nasdaq's delisting decision, temporarily halting the process.
- A 1-for-15 reverse stock split is planned to regain Nasdaq compliance, expected to be effective on or after February 13, 2026.
Related Companies
Companies in the same industry (SIC: 8071)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.